Pharmacological control of receptor of ddvanced glycation end-products and its biological effects in psoriasis

International Journal of Biomedical Science

Volumn 9, Issue 3, 2013, Pages 112-122

  Mezentsev, A V ^a   Bruskin, S A ^a   Soboleva, A G ^a   Sobolev, V V ^a   Piruzian, E S ^a  

^a VAVILOV INSTITUTE OF GENERAL GENETICS   (Russian Federation)

Author keywords

AGE; JAK kinases; KIOM 79; Psoriasis; RAGE; SAGE; Tyrphostins

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; BENAZEPRIL; CAPTOPRIL; DIMETHOXYQUINAZOLINE; ENALADEX; ENALAPRIL; ENALAPRIL MALEATE; GLYCOSAMINOGLYCAN; GM 1111; HERBACEOUS AGENT; IMATINIB; JANUS KINASE; JANUS KINASE INHIBITOR; KIOM 79; METFORMIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NC 1153; PERINDOPRIL; PF 956980; PLACEBO; PNU 156804; RAMIPRIL; RAMIPRILAT; RUXOLITINIB; SORAFENIB; SULFATED ANIONIC GLYCOSAMINOGLYCAN ETHER; SUNITINIB; TOFACITINIB; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTINIC KERATOSIS; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; DRUG MECHANISM; DYSESTHESIA; EDEMA; ERYTHEMA; ERYTHROCYTE COUNT; EXTRACELLULAR MATRIX; FACE ERYTHEMA; HEADACHE; HUMAN; IMMUNE RESPONSE; LEUKOCYTE COUNT; MACULOPAPULAR RASH; NAUSEA; NONHUMAN; PERIORBITAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN CROSS LINKING; PSORIASIS; RESPIRATORY TRACT INFECTION; REVIEW; SCALP DYSESTHESIA; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION;

EID: 84884570632     PISSN: 15509702     EISSN: 15552810     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin. Dermatol. 2007; 25 (6): 535-546.
2. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin. Exp. Dermatol. 2001; 26 (4): 314-320.
3. Piruzian ES, Sobolev VV, Abdeev RM, et al. Study of Molecular Mechanisms Involved in the Pathogenesis of Immune-Mediated Inflammatory Diseases, using Psoriasis As a Model. Acta. naturae. 2009; 1 (3): 125-135.
4. Zhukova OV, Shneider IV, Morozova I, et al. Genetic markers and psoriasis in three ethnic populations of Dagestan. Genetika. 2005; 41 (12): 1702-1706.
5. Goldenkova-Pavlova IV, Piruzian AL, et al. Population analysis and determination of the ethnic background are necessary in the study of multifactorial diseases: a study using the Dagestan population as a model. Genetika. 2006; 42 (8): 1137-1142.
6. Clynes R, Moser B, Yan SF, et al. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr. Mol. Med. 2007; 7 (8): 743-751.
7. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 2001; 108 (7): 949-955.
8. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia. 2009; 52 (11): 2251-2263.
9. Piruzian E, Bruskin S, Ishkin A, et al. Integrated network analysis of transcriptomic and proteomic data in psoriasis. BMC systems biology. 2010; 4: 41.
10. Riehl A, Nemeth J, Angel P, Hess J. The receptor RAGE: Bridging inflammation and cancer. Cell Commun. Signal. 2009; 7: 12.
11. Riehl A, Bauer T, Brors B, et al. Identification of the Rage-dependent gene regulatory network in a mouse model of skin inflammation. BMC Genomics. 2010; 11: 537.
12. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 2000; 192 (4): 565-570.
13. Rouhiainen A, Kuja-Panula J, Wilkman E, et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood. 2004; 104 (4): 1174-1182.
14. Hudson BI, Kalea AZ, Del Mar Arriero M, et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligandstimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem. 2008; 283 (49): 34457-34468.
15. Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008; 22 (10): 3716-3727.
16. Schreiber J, Jenner RG, Murray HL, et al. Coordinated binding of NF-κB family members in the response of human cells to lipopolysaccharide. Proc. Natl. Acad. Sci. U. S. A. 2006; 103 (15): 5899-5904.
17. Wolf R, Mascia F, Dharamsi A, et al. Gene from a psoriasis susceptibility locus primes the skin for inflammation. Sci. Trans. l. Med. 2010; 2 (61): 61ra90.
18. Luan ZG, Zhang H, Yang PT, et al. HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-alpha in human umbilical vein endothelial cells. Immunobiology. 2010; 215 (12): 956-962.
19. Fu MX, Wells-Knecht KJ, Blackledge JA, et al. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994; 43 (5): 676-683.
20. Damasiewicz-Bodzek A, Wielkoszynski T. Advanced protein glycation in psoriasis. J. Eur. Acad. Dermatol. Venereol. 2012; 26 (2): 172-179.
21. Vasan S, Zhang X, Kapurniotu A, et al. An agent cleaving glucosederived protein crosslinks in vitro and in vivo. Nature. 1996; 382 (6588): 275-278.
22. Thornalley PJ, Minhas HS. Rapid hydrolysis and slow alpha, betadicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochem. Pharmacol. 1999; 57 (3): 303-307.
23. Wolffenbuttel BH, Boulanger CM, Crijns FR, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl. Acad. Sci. U. S. A. 1998; 95 (8): 4630-4634.
24. Rahbar S, Kumar Yernini K, Scott S, et al. Novel inhibitors of advanced glycation endproducts. Biochem. Biophys. Res. Commun. 1999; 262 (3): 651-656.
25. Rahbar S, Yerneni KK, Scott S, et al. Novel inhibitors of advanced glycation endproducts (part II). Mol. Cell. Biol. Res. Commun. 2000; 3 (6): 360-366.
26. Rahbar S, Natarajan R, Yerneni K, et al. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. Acta. 2000; 301 (1-2): 65-77.
27. Cheng G, Wang LL, Qu WS, et al. C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats. Acta Pharmacol. Sin. 2005; 26 (12): 1460-1466.
28. Ulrich P, Zhang X. Pharmacological reversal of advanced glycation end-product-mediated protein crosslinking. Diabetologia. 1997; 40 (Suppl 2): S157-S159.
29. Watson AM, Soro-Paavonen A, Sheehy K, et al. Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia. 2011; 54 (3): 681-689.
30. Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res. 2003; 92 (7): 785-792.
31. Tikellis C, Thomas MC, Harcourt BE, et al. Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. Am. J. Physiol. Endocrinol. Metab. 2008; 295 (2): E323-E330.
32. Guo Y, Lu M, Qian J, Cheng YL. Alagebrium chloride protects the heart against oxidative stress in aging rats. J. Gerontol. A Biol. Sci. Med. Sci. 2009; 64 (6): 629-635.
33. Kim JB, Song BW, Park S, et al. Alagebrium chloride, a novel advanced glycation end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model. Korean Circ J. 2010; 40 (10): 520-526.
34. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001; 104 (13): 1464-1470.
35. Sell DR, Monnier VM. Molecular Basis of Arterial Stiffening: Role of Glycation. Gerontology. 2012; 58 (3): 227-237.
36. Biemel KM, Lederer MO. Site-specific quantitative evaluation of the protein glycation product N6-(2, 3-dihydroxy-5, 6-dioxohexyl)-Llysinate by LC-(ESI)MS peptide mapping: evidence for its key role in AGE formation. Bioconjug. Chem. 2003; 14 (3): 619-628.
37. Yang S, Litchfield JE, Baynes JW. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch. Biochem. Biophys. 2003; 412 (1): 42-46.
38. Mentink CJ, Hendriks M, Levels AA, Wolffenbuttel BH. Glucosemediated cross-linking of collagen in rat tendon and skin. Clin. Chim. Acta. 2002; 321 (1-2): 69-76.
39. Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 2001; 276 (52): 48967-48972.
40. Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr. Drug Targets. 2005; 6 (4): 453-474.
41. Monnier VM, Sell DR. Prevention and repair of protein damage by the Maillard reaction in vivo. Rejuvenation Res. 2006; 9 (2): 264-273.
42. Babaei-Jadidi R, Karachalias N, Ahmed N, et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes. 2003; 52 (8): 2110-2120.
43. Kim T, Spiegel DA. The unique reactivity of N-phenacyl-derived thiazolium salts toward alpha-dicarbonyl compounds. Rejuvenation Res. 2012; 16 (1): 43-50.
44. Capek P, Hribalova V. Water-soluble polysaccharides from Salvia officinalis L. possessing immunomodulatory activity. Phytochemistry. 2004; 65 (13): 1983-1992.
45. Zhang J, Xu X, Rao NV, et al. Novel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosacea. PloS One. 2011; 6 (2): e16658.
46. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat. Med. 2007; 13 (8): 975-980.
47. Morizane S, Yamasaki K, Kabigting FD, Gallo RL. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid. J. Invest. Dermatol. 2010; 130 (5): 1297-1306.
48. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-and P-selectins. J. Clin. Invest. 2002; 110 (1): 127-136.
49. Kim YS, Jung DH, Kim NH, et al. KIOM-79 inhibits high glucose or AGEs-induced VEGF expression in human retinal pigment epithelial cells. J. Ethnopharmacol. 2007; 112 (1): 166-172.
50. Kim J, Kim CS, Sohn E, et al. KIOM-79 Prevents Lens Epithelial Cell Apoptosis and Lens Opacification in Zucker Diabetic Fatty Rats. Evid. Based Complement Alternat. Med. 2011; 2011. doi: pii: 717921. 10. 1155/2011/717921.
51. Jung DH, Kim YS, Kim JS. KIOM-79 prevents S100b-induced TGFbeta1 and fibronectin expression in mouse mesangial cells. J. Ethnopharmacol. 2009; 125 (3): 374-379.
52. Kang KA, Kim JS, Zhang R, et al. Induction of heme oxygenase-1 by plant extract KIOM-79 via Akt pathway and NF-E2 related factor 2 in pancreatic beta-cells. J. Toxicol. Environ. Health A. 2008; 71 (20): 1392-1399.
53. Jeon YJ, Li MH, Lee KY, et al. KIOM-79 inhibits LPS-induced iNOS gene expression by blocking NF-κB/Rel and p38 kinase activation in murine macrophages. J. Ethnopharmacol. 2006; 108 (1): 38-45.
54. Kim NH, Kim YS, Jung DH, Kim JS. KIOM-79 prevents xyloseinduced lens opacity and inhibits TGF-beta2 in human lens epithelial cells cultured under high glucose. J. Ethnopharmacol. 2010; 130 (3): 599-606.
55. Kang KA, Lee KH, Kim SY, et al. Cytoprotective effects of KIOM-79 on streptozotocin induced cell damage by inhibiting ERK and AP-1. Biol. Pharm. Bull. 2007; 30 (5): 852-858.
56. Sohn E, Kim J, Jeong IH, et al. Combination of Medicinal Herbs KIOM-79 Reduces Advanced Glycation End Product Accumulation and the Expression of Inflammatory Factors in the Aorta of Zucker Diabetic Fatty Rats. Evid. Based Complement Alternat. Med. 2011; 2011: 784136.
57. Kang KA, Kim JS, Zhang R, et al. Effect of KIOM-79 against mitochondrial damage induced by streptozotocin in pancreatic beta-cells. J. Toxicol. Environ. Health A. 2009; 72 (20): 1201-1208.
58. Kim CS, Sohn EJ, Kim YS, et al. Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats. J. Ethnopharmacol. 2007; 111 (2): 240-247.
59. Yasui C. Changes in the intracellular free calcium of cultured human epidermal keratinocytes. The Hokkaido J. Med. Sci. 1991; 66 (2): 111-121.
60. Steckelings UM, Artuc M, Paul M, et al. Angiotensin II stimulates proliferation of primary human keratinocytes via a non-AT1, non-AT2 angiotensin receptor. Biochem. Biophys. Res. Commun. 1996; 229 (1): 329-333.
61. Steckelings UM, Czarnetzki BM. The renin-angiotensin-system in the skin. Evidence for its presence and possible functional implications. Exp. Dermatol. 1995; 4 (6): 329-334.
62. Forbes JM, Thorpe SR, Thallas-Bonke V, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 2005; 16 (8): 2363-2372.
63. Fraser A, Fearon U, Reece R, et al. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum. 2001; 44 (9): 2024-2028.
64. Nangaku M, Miyata T, Sada T, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J. Am. Soc. Nephrol. 2003; 14 (5): 1212-1222.
65. Liu XP, Pang YJ, Zhu WW, et al. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Arthritis Rheum. 2009; 36 (3): 287-296.
66. Huang JS, Guh JY, Chen HC, et al. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J. Cell. Biochem. 2001; 81 (1): 102-113.
67. Madeddu P, Ena P, Dessi-Fulgheri P, et al. Captopril-induced proteinuria in hypertensive psoriatic patients. Nephron. 1986; 44 (4): 358-360.
68. Wolf R, Dorfman B, Krakowski A. Psoriasiform eruption induced by captopril and chlorthalidone. Cutis. 1987; 40 (2): 162-164.
69. Wolf R, Tamir A, Brenner S. Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica. 1990; 181 (1): 51-53.
70. Thestrup-Pedersen K. Adverse reactions in the skin from anti-hypertensive drugs. Dan. Med. Bull. 1987; 34 (Suppl 1): 3-5.
71. Kitamura K, Aihara M, Osawa J, et al. Sulfhydryl drug-induced eruption: a clinical and histological study. J. Dermatol. 1990; 17 (1): 44-51.
72. Hauschild TT, Bauer R, Kreysel HW. Initial manifestation of eruptive exanthematous psoriasis vulgaris caused by captopril medication. Der Hautarzt. 1986; 37 (5): 274-277.
73. Antonov D, Grozdev I, Pehlivanov G, Tsankov N. Psoriatic erythroderma associated with enalapril. Skinmed. 2006; 5 (2): 90-92.
74. Thakor P, Padmanabhan M, Johnson A, et al. Ramipril-induced generalized pustular psoriasis: case report and literature review. Am. J. Ther. 2010; 17 (1): 92-95.
75. Eriksen JG, Christiansen JJ, Asmussen I. Postulosis palmoplantaris caused by angiotensin-converting enzyme inhibitors. Ugeskr. Laeger. 1995; 157 (23): 3335-3336.
76. Ben-Bassat H, Klein BY. Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr. Pharm. Des. 2000; 6 (9): 933-942.
77. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003; 101 (9): 3597-3605.
78. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003; 9 (1): 327-337.
79. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab. 2006; 91 (10): 4070-4076.
80. Rosenbaum SE, Wu S, Newman MA, et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008; 16 (6): 557-566.
81. Keshtgarpour M, Dudek AZ. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl. Res. 2007; 149 (3): 103-106.
82. Narayanan S, Callis-Duffin K, et al. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am. J. Med. Sci. 2010; 339 (6): 580-581.
83. Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin. Genitourin. Cancer. 2009; 7 (1): 20-23.
84. Degen A, Satzger I, Voelker B, et al. Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? Dermatology. 2010; 221 (3): 193-196.
85. Kong HH, Turner ML. Array of cutaneous adverse effects associated with sorafenib. J. Am. Acad. Dermatol. 2009; 61 (2): 360-361.
86. Rubsam K, Flaig MJ, Ruzicka T, Prinz JC. Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib. J. Am. Acad. Dermatol. 2011; 64 (6): 1194-1196.
87. Kong HH, Cowen EW, Azad NS, et al. Keratoacanthomas associated with sorafenib therapy. J. Am. Acad. Dermatol. 2007; 56 (1): 171-172.
88. Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch. Dermatol. 2008; 144 (7): 886-892.
89. Diamantis ML, Chon SY. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. J Drugs Dermatol. 2010; 9 (2): 169-171.
90. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J. Drugs Dermatol. 2006; 5 (3): 228-231.
91. Miyagawa S, Fujimoto H, Ko S, et al. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br. J. Dermatol. 2002; 147 (2): 406-407.
92. Woo SM, Huh CH, Park KC, Youn SW. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J. Dermatol. 2007; 34 (10): 724-726.
93. Cheng H, Geist DE, Piperdi M, et al. Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour. Australas. J. Dermatol. 2009; 50 (1): 41-43.
94. Shimizu K, Kuroda H, Kida M, et al. Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia. Rinsho Ketsueki. 2005; 46 (10): 1152-1155.
95. Trivin F, Boucher E, Raoul JL. Complete sustained regression of extensive psoriasis with cetuximab combination chemotherapy. Acta Oncol. 2004; 43 (6): 592-593.
96. Neyns B, Meert V, Vandenbroucke F. Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis. Curr. Oncol. 2008; 15 (4): 196-197.
97. Giroux Leprieur E, Friard S, Couderc LJ. Improvement of psoriasis in a lung cancer patient treated with erlotinib. Eur. J. Dermatol. 2010; 20 (2): 243-244.
98. Zorzou MP, Stratigos A, Efstathiou E, Bamias A. Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor. Acta Derm. Venereol. 2004; 84 (4): 308-309.
99. Deguchi N, Kawamura T, Shimizu A, et al. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia. Br. J. Dermatol. 2006; 154 (6): 1216-1218.
100. Campbell TM, Brown CW, Jr. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy. J. Drugs Dermatol. 2008; 7 (12): 1161-1163.
101. Fournier C, Tisman G. Sorafenib-associated remission of psoriasis in hypernephroma: case report. Dermatol. Online J. 2010; 16 (2): 17.
102. Dickens E, Lewis F, Bienz N. Imatinib: a designer drug, another cutaneous complication. Clin. Exp. Dermatol. 2009; 34 (5): 603-604.
103. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu. Rev. Immunol. 1998; 16: 293-322.
104. Martino A, Holmes JH, Lord JD, et al. Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J. Immunol. 2001; 166 (3): 1723-1729.
105. Darnell JE, Jr. STATs and gene regulation. Science. 1997; 277 (5332): 1630-1635.
106. Nagy ZS, LeBaron MJ, Ross JA, et al. STAT5 regulation of BCL10 parallels constitutive NFκB activation in lymphoid tumor cells. Mol. Cancer. 2009; 8: 67.
107. Saijo K, Park SY, Ishida Y, et al. Crucial role of Jak3 in negative selection of self-reactive T cells. J. Exp. Med. 1997; 185 (2): 351-356.
108. Notarangelo LD, Giliani S, Mazza C, et al. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol. Rev. 2000; 178: 39-48.
109. Thomis DC, Berg LJ. Peripheral expression of Jak3 is required to maintain T lymphocyte function. J. Exp. Med. 1997; 185 (2): 197-206.
110. Thomis DC, Gurniak CB, Tivol E, et al. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science. 1995; 270 (5237): 794-797.
111. Nosaka T, van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science. 1995; 270 (5237): 800-802.
112. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer cell. 2006; 10 (1): 65-75.
113. Cornejo MG, Kharas MG, Werneck MB, et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood. 2009; 113 (12): 2746-2754.
114. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996; 379 (6566): 645-648.
115. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003; 302 (5646): 875-878.
116. Williams NK, Bamert RS, Patel O, et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 2009; 387 (1): 219-232.
117. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690, 550). J. Immunol. 2011; 186 (7): 4234-4243.
118. Goka AK, Rolston DD, Mathan VI, Farthing MJ. Diagnosis of Strongyloides and hookworm infections: comparison of faecal and duodenal fluid microscopy. Trans. R. Soc. Trop. Med. Hyg. 1990; 84 (6): 829-831.
119. Rosengren S, Corr M, Firestein GS, Boyle DL. The JAK inhibitor CP-690, 550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann. Rheum. Dis. 2012; 71 (3): 440-447.
120. van Gurp E, Weimar W, Gaston R, et al. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am. J. Transplant. 2008; 8 (8): 1711-1718.
121. Ju W, Zhang M, Jiang JK, et al. CP-690, 550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood. 2011; 117 (6): 1938-1946.
122. Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690, 550 in patients with psoriasis. J. Invest. Dermatol. 2009; 129 (9): 2299-2302.
123. Sudbeck EA, Liu XP, Narla RK, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. 1999; 5 (6): 1569-1582.
124. Changelian PS, Moshinsky D, Kuhn CF, et al. The specificity of JAK3 kinase inhibitors. Blood. 2008; 111 (4): 2155-2157.
125. Uckun FM, Ek O, Liu XP, Chen CL. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6, 7-dimethoxyquinazoline]. Clin. Cancer Res. 1999; 5 (10): 2954-2962.
126. Tibbles HE, Vassilev A, Wendorf H, et al. Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J. Biol. Chem. 2001; 276 (21): 17815-17822.
127. Podder H, Kahan BD. Janus kinase 3: a novel target for selective transplant immunosupression. Am. J. Transplant. 2004; 8 (6): 613-629.
128. Stepkowski SM, Kao J, Wang ME, et al. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J. Immunol. 2005; 175 (7): 4236-4246.
129. Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int. J. Clin. Pharmacol. Ther. 1996; 34 (11): 515-519.
130. Mortellaro A, Songia S, Gnocchi P, et al. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-κ B and AP-1 activation. J. Immunol. 1999; 162 (12): 7102-7109.
131. Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J. Immunol. 2009; 183 (3): 2183-2192.
132. Deuse T, Velotta JB, Hoyt G, et al. Novel immunosuppression: R348, a JAK3-and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation. 2008; 85 (6): 885-892.
133. Velotta JB, Deuse T, Haddad M, et al. A novel JAK3 inhibitor, R348, attenuates chronic airway allograft rejection. Transplantation. 2009; 87 (5): 653-659.
134. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs. 2010; 13 (6): 394-403.
135. Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J. Am. Acad. Dermatol. 2012; 67 (4): 658-664.
136. Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J. Invest. Dermatol. 2011; 131 (9): 1838-1844.
137. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115 (15): 3109-3117.
138. Kwatra SG, Dabade TS, Gustafson CJ, Feldman SR. JAK inhibitors in psoriasis: a promising new treatment modality. J. Drugs Dermatol. 2012; 11 (8): 913-918.
139. Lin TH, Hegen M, Quadros E, et al. Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. Arthritis Rheum. 2010; 62 (8): 2283-2293.